Swedencare AB (publ)

OTCPK:SWDC.F Stock Report

Market Cap: US$682.8m

Swedencare Past Earnings Performance

Past criteria checks 5/6

Swedencare has been growing earnings at an average annual rate of 23.3%, while the Pharmaceuticals industry saw earnings declining at 0.3% annually. Revenues have been growing at an average rate of 53% per year. Swedencare's return on equity is 1%, and it has net margins of 3.1%.

Key information

23.3%

Earnings growth rate

7.3%

EPS growth rate

Pharmaceuticals Industry Growth6.0%
Revenue growth rate53.0%
Return on equity1.0%
Net Margin3.1%
Next Earnings Update23 Oct 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Swedencare makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OTCPK:SWDC.F Revenue, expenses and earnings (SEK Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 242,472768590
31 Mar 242,414728300
31 Dec 232,338598030
30 Sep 232,199877360
30 Jun 232,085537260
31 Mar 231,987976900
31 Dec 221,843956400
30 Sep 221,600985470
30 Jun 221,3351054560
31 Mar 221,019603450
31 Dec 21773552590
30 Sep 21618402050
30 Jun 21465441460
31 Mar 21337341140
31 Dec 2024033870
30 Sep 2017434720
30 Jun 2013628610
31 Mar 2013430580
31 Dec 1912730540
30 Sep 1912130500
30 Jun 1911328480
31 Mar 1910827470
31 Dec 189923440
30 Sep 189423410
30 Jun 189220420
31 Mar 188517410
31 Dec 178617400
30 Sep 177812390
30 Jun 177011350
31 Mar 176312310
31 Dec 165410280
30 Sep 16439230
30 Jun 16378190
31 Mar 16348150
31 Dec 15277100
31 Dec 1424490
31 Dec 1318090

Quality Earnings: SWDC.F has high quality earnings.

Growing Profit Margin: SWDC.F's current net profit margins (3.1%) are higher than last year (2.5%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: SWDC.F's earnings have grown significantly by 23.3% per year over the past 5 years.

Accelerating Growth: SWDC.F's earnings growth over the past year (43.3%) exceeds its 5-year average (23.3% per year).

Earnings vs Industry: SWDC.F earnings growth over the past year (43.3%) exceeded the Pharmaceuticals industry 13%.


Return on Equity

High ROE: SWDC.F's Return on Equity (1%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies